"Obviously we're re-examining the current price of Emflaza … We believe a change needs to be had, but … it's really too premature to speculate on the price level," commented Dr. Stuart Peltz, CEO of PTC Therapeutics in yesterday's conference call. The biopharmaceutical company is focused on developing drugs for rare diseases and other underserved patient communities. PTC plans to pay Marathon $75 million in cash and $65 million in stock for commercialization rights for Emflaza. The company is also awaiting regulatory approval of its own DMD drug candidate, Translarna. "With our nearly 20-year commitment to the Duchenne community, it is deeply meaningful for us to bring this critical therapy to US patients," said Peltz. "We believe Emflaza is a disease-modifying therapy that has been shown to slow disease progression. In keeping with PTC's mission, we are excited to work with the community to raise the standard of care for DMD patients." Emflaza is a steroid drug designed to reduce inflammation and the immune response in all patients with DMD.